Breakthrough pain in oncology: a longitudinal study. by Mercadante, S. et al.
Vol. 40 No. 2 August 2010 Journal of Pain and Symptom Management 183Original ArticleBreakthrough Pain in Oncology:
A Longitudinal Study
Sebastiano Mercadante, MD, Vittoria Zagonel, MD, Enrico Breda, MD,
Carlo Arcara, MD, Vittorio Gebbia, MD, Giampiero Porzio, MD,
Federica Aielli, MD, Fabrizio David, MD, Teresa Gammucci, MD,
Filomena Narducci, MD, Gaetano Lanzetta, MD, Rossella Restuccia, MD,
Alessandro Lembo, MD, Virginia Passeri, MD, Vladimir Virzı`, MD,
and Alessandra Casuccio, BS
Pain Relief and Palliative Care Unit (S.M., F.D.) and Department of Oncology (C.A., V.G., G.P., F.A.),
La Maddalena Cancer Center, Palermo; Palliative Medicine (S.M.), Department of Anesthesia &
Intensive Care, and Department of Clinical Neuroscience (A.C.), University of Palermo, Palermo;
Department of Oncology (V.Z., E.B.), Ospedale Fatebenefratelli, Rome; Department of Oncology
(T.G., F.N.), Ospedale SS Trinita` Sora, Rome; Department of Oncology (G.L., R.R.),
Istituto Neurotraumatologico Italiano, Grottaferrata, Rome; Department of Oncology (A.L., V.P.),
Casa di Cura Marco Polo, Rome; and Department of Oncology (V.V.), University Campus
Biomedico, Rome, ItalyAbstract
Context. Existing studies on breakthrough pain (BP) have reported different
prevalence rates because of different settings, populations, and assessment
methods. These studies have used cross-sectional designs, and the relationship of
BP with analgesic treatment has not been evaluated.
Objectives. The aim of this study was to longitudinally assess BP in cancer
patients admitted to oncology units.
Methods. A consecutive sample of patients admitted to oncology centers was
selected. At admission (T0), three months after admission (T3), and six months
after admission (T6), data on background pain and BP were recorded. BP was
assessed in terms of its intensity, duration, number of episodes, onset with
movement, spontaneous relief after stopping activity, limitation of physical activity,
and effectiveness of analgesics.
Results. Three hundred two patients completed the study. At T0, T3, and T6,
39%, 38%, and 33% patients, respectively, had continuous pain (P¼ 0.294). Pain
intensity significantly decreased (P¼ 0.004 and 0.027 at T3 and T6, respectively).
Most patients had BP at T0 (87.1%), T3 (80.9%), and T6 (73.2%), and there was
a significant decrease in the prevalence of BP over time (P¼ 0.016). Of 149
patients with BP, pain on movement was recorded in 43.6%, 43.4%, and 32.4% at
T0, T3, and T6, respectively (P¼ 0.228). Pain spontaneously decreased or ceased
when stopping physical activity in 66%, 56%, and 62% at T0, T3, and T6,Address correspondence to: Sebastiano Mercadante,
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184 Vol. 40 No. 2 August 2010Mercadante et al.respectively (P¼ 0.537). Pain on movement strongly limited physical activity in
most patients.
Conclusion. These data expand current information about BP and underline
the need for a longitudinal assessment of a phenomenon that is invariably
dependent on stage of disease, patient, and therapeutic factors. J Pain Symptom
Manage 2010;40:183e190.  2010 U.S. Cancer Pain Relief Committee. Published by
Elsevier Inc. All rights reserved.Key Words
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In the cancer population, breakthrough
pain (BP) is a transitory flare of pain superim-
posed on an otherwise stable pain pattern in
patients treated with opioids.1 Several cross-
sectional studies have reported a variable
prevalence, dependent on the setting, such
as hospice admission, oncology inpatient, or
pain clinic. In an international survey per-
formed in a wide range of patients with pain
severe enough to be treated with opioids,
a BP prevalence of about 65% was found,
and BP was associated with poor pain control
and functional impairment.2 In advanced can-
cer patients followed by palliative care physi-
cians in different settings, including hospice
and home care, BP had a prevalence of
86%e93%,3e5 whereas in other studies with
a mixed population, a lower prevalence
(41%e51%) was found.6,7 In an outpatient
pain clinic, BP was found in 39% of patients.8
All these data occur in the context of chronic
pain; oncology outpatients and inpatients
admitted with uncontrolled pain have an
overall prevalence of 70%.9
It is likely that different settings, popula-
tions, and assessment methods may produce
different results in surveys of BP. Moreover, ex-
isting studies are cross-sectional, and no study
has assessed changes in BP over time during
the course of disease and the possible relation-
ship with the analgesic treatment. For exam-
ple, one type of BP, incident pain because of
movement in patients with bone metastases,
may be influenced by physical activity, which
is dependent on the stage of disease or
response to oncologic treatment. Moreover,
patients receive an analgesic treatment that
can be either effective or insufficient, andthe outcome strongly influences the feature
of BP. In other words, the entity of BP is strictly
linked to the clinical scenario, rather than
a phenomenon of pain, independent from
other variables.
Patients with cancer pain can be placed at
two extremes, with a large variability between
these points: patients who are receiving onco-
logic treatment are quite different from ad-
vanced cancer patients with a short survival
followed at home. Because of the dynamic
course of cancer disease and analgesic
regimen, it is likely that changes in these com-
ponents influence BP.
The aim of the present project was to longi-
tudinally assess BP in different settings accord-
ing to the different stages of disease and
treatments. The present study assessed pa-
tients in oncology units longitudinally fol-
lowed over a period of six months during the
course of disease. Data regarding advanced
cancer patients who were followed at home
have been the subject of a concomitant study
with a similar but shorter design.Patients and Methods
This survey was a prospective, longitudinal,
observational study. An investigator meeting
was held to explain to each responsible center
participating in the study the procedures for
assessing BP and other details of the study. In-
formed consent and approval of ethics com-
mittees were obtained.
A specific chart was designed to gather study
information from patients at time of inclusion
and for the following assessments (visit or tele-
phone). A consecutive sample of patients ad-
mitted to different oncology centers in Italy
Table 1
Characteristics of Surveyed Patients
Characteristic Value
No. of participants 435
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2007 was recruited. Patients could be in the
day hospital, inpatient units, or outpatient
clinic. The patients who gave their informed
consent to participate in the study were as-
sessed and surveyed for a period of six months.
Patients were excluded if they had a survival
expectation of less than six months or were
cognitively impaired or too unwell to provide
reliable answers to questions regarding data
collection.
After the screening, common epidemiologic
data, the presence of continuous pain and its
intensity (on a numerical scale from 0 to 10),
and the presence of BP were recorded. If BP
was reported, it was assessed according to in-
tensity (on a numerical scale from 0 to 10), du-
ration, number of episodes, whether induced
by movement, and whether there was sponta-
neous relief after stopping activity. The severity
of limitation of physical activity because of
pain on movement was graded as none (0),
lightly (1), severely (2), and completely (3).
Patients were asked information about the an-
algesic regimen for continuous pain and its
effectiveness, as well for BP, graded as none
(0), poor (1), moderate (2), and good (3),
and the use of bisphosphonates also was
recorded. Data were collected by treating phy-
sicians responsible for the study at each center.
After the initial assessment, patients re-
ceived analgesics for background pain and
BP, as well as symptomatic treatment usually
provided at each oncology center, according
to local policies and protocols, without chang-
ing routine activity. They continued their
oncologic treatments as per protocol. At three-
and six-month intervals (T3 and T6, respec-
tively), the same data collected at admission
(T0) were recorded. When patients were
unavailable for a visit, they were contacted by
phone.
Statistical Analysis
Data collected in the charts were computer-
ized and analyzed by SPSS Software (v.14.0,
SPSS, Inc., Chicago, IL). Statistical analysis of
quantitative data, including descriptive statis-
tics, was performed for all the items. The
paired Wilcoxon signed-rank test and the
paired samples Student’s t-test were used to
compare the differences in pain intensity
scores and other parameters at the timeintervals. All P-values were two-sided, and
P-values less than 0.05 were considered to indi-
cate statistical significance.Results
Four hundred thirty-five of 750 patients ini-
tially screened during the two days of the first
week of October 2007 were recruited from six
oncology centers in Italy and surveyed for this
study. Two hundred sixty-five were excluded ac-
cording to the criteria described in the protocol
or because they did not give their consent. The
characteristics of patients are described in
Table 1. Mean Eastern Cooperative Oncology
Group (ECOG) value at study entrywas 1 and re-
mained stable for the entire period of study
(Table 2). Data regarding 65 and 133 patients
were unavailable at T3 and T6, respectively.
Forty-two patients and 100 patients had died
by T3 and T6, respectively. Ten patients and
four patients moved to other hospitals by T3
and T6, respectively. Data were missing in 13
and 29 patients at T3 and T6, respectively.
At admission (T0), 171 (39%) patients had
continuous pain, with a mean (standard devia-
tion) pain intensity of 5.6 (1.9). No significant
changes were observed at T3 and T6 (38% and
33%, respectively; P¼ 0.294). Pain intensity
significantly changed at T3 and T6 (P¼ 0.004
and 0.027, respectively), as well as the effective-
ness of background analgesia (P< 0.0005 at
T3 and T6). At T0, 126 (73.7%) patients
were satisfied (moderate to good) with the
background analgesia. At T3 and T6, 133
(93%) patients and 92 (91%) patients,
Table 2
Reason for Admission and Data Regarding Continuous Pain at the Different Time Intervals
T0 T3 T6
n 435 370 302
ECOG score 1.0 (0.9) 1.0 (1.0) 1.0 (1.0)
Reason for admission
CH DH 267 140 99
CH admission 31 20 20
Symptom control or other reason 137 210 183
Continuous pain (y/n) 171/304 (39%) 142/279 (38%) 101/228 (33%)
Intensity 5.6 (1.9) 4.9 (2.2) 4.8 (2.0)
Use of strong opioids 88 (51.4%) 79 (55%) 59 (54%)
Bisphosphonates (y/n) 57 52 29
Satisfaction with treatmenta
0 20 2 1
1 25 7 8
2 69 53 29
3 57 80 63
CH DH¼ chemotherapy in day hospital; CH admission¼ chemotherapy during admission.
aSatisfaction graded as 0¼ none, 1¼ poor, 2¼moderate, and 3¼ good.
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ground analgesia. No change in the use of
strong opioids and bisphosphonates was ob-
served (Table 2).
Most of these patients had BP at T0 (87.1%),
and there was a moderate decrease at T3
(80.9%), more importantly at T6 (73.2%)
(P¼ 0.016). Intensity of BP did not change at
these time intervals (P¼ 0.635 and 0.991,
respectively). Duration of pain episodes was
mostly less than 60 minutes, and most patients
had fewer than four episodes per day. No sig-
nificant changes were observed over time in
pain duration (P¼ 0.262) or number of epi-
sodes (P¼ 0.637) (Table 2).
Of 149 patients with BP, the cause was inci-
dent pain on movement related to bone metas-
tases in 43.6%, 43.4%, and 32.4% of patients,
at T0, T3, and T6, respectively (P¼ 0.228).
The intensity of incident pain did change sig-
nificantly after six months (P¼ 0.368 and
0.011 at T3 and T6, respectively).
Pain decreased spontaneously or ceased
when stopping physical activity in 66%, 56%,
and 62%, at T0, T3, and T6, respectively
(P¼ 0.537). Pain on movement strongly lim-
ited physical activity in most patients, without
change over time, and cessation of physical ac-
tivity decreased pain on movement in about
60% of patients, also without change over
time (P¼ 0.537) (Table 3).
One hundred twenty-six (84.5%), 96 (85%),
and 59 (79%) patients were prescribeda medication for BP at T0, T3, and T6, respec-
tively (P¼ 0.033), although 23 (18.2%), 19
(19.7%), and 15 (25%), respectively, were not
taking BP medication, despite having a pre-
scription. One hundred nine (86.5%) patients
who were prescribed a BP medication were sat-
isfied with the treatment, and a similar num-
ber continued to be satisfied at T3 and T6
(Table 3), attaining a significant change at
T6 (P¼ 0.027). Seventy (55.5%) patients
were receiving strong opioids as BP medica-
tion, mainly transmucosal fentanyl and oral
morphine in a similar proportion, and a similar
number continued to receive strong opioids
for BP at the subsequent intervals.
There was a correlation between ECOG
values and basal pain intensity (P¼ 0.013), BP
intensity (P< 0.0005), and pain on movement
(P¼ 0.003). No correlation between the use of
bisphosphonates and pain intensity was found.Discussion
This survey was performed in oncology cen-
ters representative of common units providing
care for the cancer population in Italy, and it is
the first time that a longitudinal approach was
applied to gather information about the sub-
ject of BP and its treatment in this population.
Data at Admission
At inclusion in the study, about 40% of pa-
tients with a mean good performance status
Table 3
BP and BP on Movement, Limitation of Physical Activity, and Effectiveness of BP Medications
at the Different Intervals
T0 T3 T6
BP (y/n) 149/171 (87.1%) 115/142 (80.9%) 74/101 (73.2%)
Intensity 6.7 (2.0) 6.5 (1.8) 6.5 (1.9)
Duration
#30 85 69 46
>30e60 41 30 20
60e120 16 7 2
>120 7 9 6
Number of episodes
1 85 65 46
2e4 47 45 23
>4 17 5 5
BP on movement (y/n) 65/149 (43.6%) 50/115 (43.4%) 24/74 (32.4%)
Intensity 7.2 (1.9) 6.9 (1.6) 6.8 (1.6)
Cessation after stopping movement 43/65 (66.1%) 28/50 (56%) 15/24 (62.5%)
Duration
#30 34 28 14
30e60 18 17 10
60e120 10 5 0
>120 3 0 0
Grade of limitation of physical activitya
0 9 2 2
1 6 5 3
2 35 35 15
3 15 8 4
Analgesic treatment of BP 126/149 (80.5%) 96/115 (82.6%) 59/74 (79.7%)
Satisfactionb
0 6 3 0
1 11 7 5
2 55 42 23
3 54 44 31
aGraded as 0¼ none, 1¼ lightly, 2¼ severely, and 3¼ completely.
bGraded as 0¼ none, 1¼ poor, 2¼moderate, and 3¼ good.
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background analgesia. A recent large survey
performed in oncologic centers in Italy
revealed similar figures, with a 34% pain prev-
alence,10 confirming what happens in the con-
text of an oncology ward.
In this populationofpatients, the incidence of
BP was relevant and about 87% reported it. Most
patients had BP for a duration of less than 60
minutes. Most patients had one to four episodes
per day. No changes over time were observed in
these characteristics. In a concomitant study per-
formed in advanced cancer patients followed at
home, the frequency of BPwas found to be lower
(about 50%).11 Experiences in cross-sectional
studies performed in different settings report
variable figures, ranging from 39% to 86%.2e8
It is unclear whether thedurationofBP, reported
inmost epidemiologic studies of BP, is spontane-
ous or the consequence of a medical interven-
tion. This issue should be better defined and
appropriately debated.More than 40% of episodes were produced
by movement in patients with bone metastases,
with a significant decrease six months after ini-
tial evaluation. It was not possible to recognize
whether the effects were because of oncologic
treatment or a decrease of physical activity be-
cause of the progression of disease. There were
no relevant changes over time in the use of
strong opioids for background analgesia, and
a significant relationship between a worse
ECOG and background pain intensity, BP in-
tensity, and pain on movement were observed.
This confirmed previous data from the cancer
population showing that worst levels of ECOG
were associated with higher levels of pain
intensity.10
Incident pain strongly dependent on physi-
cal activity ceased or decreased after stopping
physical activity (about 60% of patients). Con-
sequently, many patients limited their physical
activity to prevent pain occurrence. This find-
ing may explain how patients with BP of
188 Vol. 40 No. 2 August 2010Mercadante et al.incident origin may have a greatly reduced
quality of life. Paradoxically, this group of pa-
tients may present no episodes of BP if they
stay at rest. For example, home care patients
with minimal physical activity, particularly
when they are close to death, are likely to
have less incident pain.11 Furthermore, if not
separately assessed, incident pain may con-
found the results of many studies performed
with drugs of rapid onset, such as transmucosal
or effervescent fentanyl, where different kinds
of BP were included. Evaluation of drug effec-
tiveness in incident pain should be assessed ac-
cording to the possibility that many of these
episodes may disappear without any interven-
tion, just stopping activity, and this may com-
plicate efforts to adjust for the placebo effect
in studies.12
A large number of patients were receiving
some BP medication at study entry. Different
figures were reported in a previous study of
hospice admissions, where 43% of patients
were prescribed no rescue medication.4 In
contrast, the rate of BP medication, mainly
oral morphine, was very high in patients sur-
veyed in Catalonia.6 As for background pain,
in advanced cancer patients discharged from
hospital to home care, a low number of pa-
tients were receiving medication for BP, but
the percentage of patients prescribed BP med-
ication doubled after one month of treatment
at home.11 Of interest, about 20% of patients
were not taking medications prescribed for
BP. This aspect already has been reported in
a previous study of a smaller sample of oncol-
ogy patients.13 Reasons for refusing BP medi-
cation included pain that was not severe
enough, pain improving before taking medica-
tion, ineffectiveness, adverse effects, concerns
about adverse effects or overdosage, or practi-
cal issues. However, the treatment of BP was
considered relatively good by a majority of
patients, possibly for the same reasons dis-
cussed for background pain.
In a survey performed in selected patients
seen in an oncology setting with predeter-
mined uncontrolled background pain, data
were reviewed one week after a visit. Of 70%
of patients initially reporting BP, only half of
them (36%) still had BP after pain manage-
ment began, suggesting that an expert inter-
vention may decrease the occurrence of BP
unmasked by the poor efficacy of backgroundmedication. Of interest, duration of BP, a me-
dian of 15 minutes, did not change despite
prescription of rescue medication, presumably
based on oral morphine, which was otherwise
considered effective by 83% of patients.9
Changes Over Time
After three and six months, 370 (85%) and
302 (69.4%) patients, respectively, were avail-
able for analysis. Despite the survival expecta-
tions and good performance status, a certain
number of patients died, and possibly some pa-
tients at study completion were particularly ad-
vanced, also explaining the preservation of the
same ECOG level in survivors.
During the study period, the proportion of
patients with background pain did not change.
Pain intensity decreased, possibly as a conse-
quence of treatments, oncologic and/or anal-
gesic, and pain treatment was considered
moderately or completely effective by most pa-
tients, although the mean value of pain inten-
sity suggests that pain was still of moderate
intensity, possibly requiring some adjustment
of analgesic therapy. Also, strong opioid con-
sumption did not change. The discrepancy be-
tween patient satisfaction and pain intensity
frequently has been reported, possibly because
of patient compliance or their specific rela-
tionship with the same professionals who are
caring for their disease. This contradiction
also was observed in a previous survey.10 Re-
search on the correlates of satisfaction with
general pain treatment indicates that patients
tend to report high levels of satisfaction, even
when pain severity remains relatively high. Dif-
ferent factors may influence patient satisfac-
tion with treatment other than the analgesic
therapy, including perceived support, high
levels of internal locus of control, various as-
pects of the patient-health care provider rela-
tionship, communication, and confidence or
trust in the treatment provider.14 Of interest,
in a survey performed in advanced cancer pa-
tients with a limited survival, a high number
of patients were unsatisfied with the previous
analgesic treatment prescribed in hospital at
time of referral to home care, when they
were visited by a subsequent professional,
namely a palliative care physician.11
The incidence of BP significantly decreased
after six months. Similarly, satisfaction with BP
medication improved during the same
Vol. 40 No. 2 August 2010 189Breakthrough Pain in Cancer Patientsinterval. These findings could be because of
the anticancer treatment received in the mean-
time, as a consequence of the natural history
of cancer and its treatment, and/or an im-
provement in analgesic therapy of background
pain and BP. The latter consideration seems
unlikely considering that the pain intensity of
background pain and the use of strong opioids
for background pain did not change. Alterna-
tively, as mentioned above, reduced physical
activity in patients close to death may have
influenced the outcome. However, the num-
ber of episodes, the BP pain intensity, and du-
ration did not change significantly, and the
number of patients with a BP prescription
did not change. Moreover, the pattern of BP
medication did not change, with strong opi-
oids, including oral transmucosal fentanyl cit-
rate, oral morphine, and oxycodone used in
about 50% of patients. Of interest, regardless
of the prescription of BP medication, 25% of
patients were not using BP medication six
months after recruitment into the study. Given
that the worst ECOG was associated with a wors-
ening pain situation, it is likely that the
changes observed in the study period are con-
sequent to oncologic treatment. This should
be better addressed in subsequent studies
with an appropriate design. It is worthwhile
to report that no changes in the use of strong
opioids for both background and BP pain were
reported during the study period, underlining
the educational need around pain manage-
ment for oncologists.
Despite generally good satisfaction, pain
control was not optimal in most patients.
This suggests a relevant role for efforts to im-
prove the patient-health care provider rela-
tionship, confidence, trust in the treatment
provider, or even dependency,14 and raises an
important question for future research. For in-
stance, when referring to home palliative care
physicians, most patients are dissatisfied with
the previous pain management provided by
oncologists.11,15,16
An important limitation to this study was the
dropout rate over time. Less than one-third of
patients dropped out before the conclusion of
the study. This finding was expected because
of the duration of the study and related lack
of adherence or compliance. Many patients
did not respond to phone calls at the time of
the interview some months after, or changedsetting, and for about 30% of them, it was ver-
ified that they died (about one-sixth of the
dropouts). This information, however, is im-
precise because no information for patients
who were not reached was available.
Another limitation of this study was the lack
of assessment of the specific oncologic thera-
pies and their possible effects on pain.17 More-
over, the lack of interrater reliability testing,
lack of validated measures, and the limited in-
formation about study dropouts, factors com-
monly related to the nature of a multicenter
observational study, may limit the generaliz-
ability of data.Conclusions
Data regarding BP remain quite controver-
sial in the literature, mainly because of differ-
ent settings, influence of the treatment, and
lack of longitudinal perspective in assessing
cancer patients. This study showed the change
in BP prevalence over time in a cancer popula-
tion followed in a typical clinical scenario
where disease and its treatment, as well as
pain and its treatment, interact. Paradoxically,
this phenomenon should be studied in pa-
tients who are receiving no analgesic treat-
ment, which is ethically unacceptable and
unrealistic and contradicts the original defini-
tion of BP, or in different conditions where pa-
tients are receiving analgesics with no, partial,
or adequate pain relief. In other words, it is
difficult to have a clear idea about a complex
phenomenon, and a prospective evaluation
may help in understanding what happens in
an individual patient. For example, one can as-
sume that the incidence of BP, particularly
movement-related pain, may decrease with
the worsening of disease, as a consequence of
a reduced level of activity or because patients
stop even minimal activity after feeling an in-
crease in pain intensity. Alternatively, a better
analgesic approach may limit the occurrence
of BP episodes. The change in physical activity,
as well as analgesic regimen, modifies the gen-
eral view about BP when longitudinally exam-
ined. This feature underlines the need for
a longitudinal assessment of a phenomenon
that is invariably dependent on stage of dis-
ease, patient, and therapeutic factors. In other
words, this phenomenon is impossible to assess
as a pure event, which in any case is influenced
190 Vol. 40 No. 2 August 2010Mercadante et al.by activity or analgesic regimen. This approach
reflects what happens in clinical practice, in
oncology centers, where the analgesic treat-
ment could not be optimal. Further studies
should examine more specifically how and
how much oncologic treatments are able to in-
fluence the natural history of cancer pain dur-
ing the progression of disease, in a very large
sample of patients divided into several
subclasses.References
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